Roivant Sciences (ROIV) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $33.53, -1.50% vs the prior close of $34.04.
- Volume 4.92M shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ROIV dips 1.5% to $33.53. Closed at $33.53, -1.50% vs the prior close of $34.04. Day range $33.23–$34.12, opened at $34.12.
ROIV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ROIV dips 1.5% to $33.53
- Closed at $33.53, -1.50% vs the prior close of $34.04. Day range $33.23–$34.12, opened at $34.12.
- Volume was 4.92M shares, 0.6x its 50-day average of 7.74M.
- Price is -8.5% vs its 50-day average ($36.63) and +8.9% vs its 200-day average ($30.79).
- 52-week range $16.88–$42.50; today's close sits at 65% of that range, 21.1% below the 52-week high.
Oct 15, 2026 — ROIV rises 1.2% to $34.04
- Closed at $34.04, +1.25% vs the prior close of $33.62. Day range $33.70–$34.35, opened at $33.82.
- Volume was 4.57M shares, 0.6x its 50-day average of 7.76M — lighter than usual.
- Price is -7.2% vs its 50-day average ($36.67) and +10.8% vs its 200-day average ($30.73).
- 52-week range $16.41–$42.50; today's close sits at 68% of that range, 19.9% below the 52-week high.
Oct 14, 2026 — ROIV rises 0.8% to $33.62
- Closed at $33.62, +0.81% vs the prior close of $33.35. Day range $33.00–$34.09, opened at $33.14.
- Volume was 4.29M shares, 0.6x its 50-day average of 7.79M — lighter than usual.
- Price is -8.3% vs its 50-day average ($36.68) and +9.6% vs its 200-day average ($30.67).
- 52-week range $16.00–$42.50; today's close sits at 66% of that range, 20.9% below the 52-week high.
Oct 13, 2026 — ROIV slides 3.6% to $33.35, a 1-month low
- Closed at $33.35, -3.58% vs the prior close of $34.59. Day range $33.26–$34.92, opened at $34.44.
- Volume was 6.32M shares, 0.8x its 50-day average of 7.79M.
- Price is -9.1% vs its 50-day average ($36.70) and +9.0% vs its 200-day average ($30.61).
- 52-week range $15.99–$42.50; today's close sits at 65% of that range, 21.5% below the 52-week high.
Oct 12, 2026 — ROIV dips 2.4% to $34.59
- Closed at $34.59, -2.40% vs the prior close of $35.44. Day range $34.55–$35.41, opened at $34.92.
- Volume was 4.73M shares, 0.6x its 50-day average of 7.80M.
- Price is -5.7% vs its 50-day average ($36.70) and +13.2% vs its 200-day average ($30.56).
- 52-week range $15.90–$42.50; today's close sits at 70% of that range, 18.6% below the 52-week high.
Oct 9, 2026 — ROIV jumps 3.6% to $35.44
- Closed at $35.44, +3.60% vs the prior close of $34.21. Day range $34.15–$35.59, opened at $34.24.
- Volume was 5.53M shares, 0.7x its 50-day average of 7.78M.
- Price is -3.4% vs its 50-day average ($36.68) and +16.2% vs its 200-day average ($30.49).
- 52-week range $15.90–$42.50; today's close sits at 73% of that range, 16.6% below the 52-week high.
Oct 8, 2026 — ROIV dips 1.6% to $34.21, a 1-month low, 3 down days in a row
- Closed at $34.21, -1.55% vs the prior close of $34.75. Day range $33.32–$34.56, opened at $34.28.
- Volume was 6.40M shares, 0.8x its 50-day average of 7.75M.
- Price is -6.7% vs its 50-day average ($36.66) and +12.4% vs its 200-day average ($30.43).
- 52-week range $15.90–$42.50; today's close sits at 69% of that range, 19.5% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ROIV dips 2.2% to $34.75, a 1-month low
- Closed at $34.75, -2.20% vs the prior close of $35.53. Day range $34.63–$35.49, opened at $35.22.
- Volume was 5.74M shares, 0.7x its 50-day average of 7.72M.
- Price is -5.1% vs its 50-day average ($36.64) and +14.4% vs its 200-day average ($30.37).
- 52-week range $15.25–$42.50; today's close sits at 72% of that range, 18.2% below the 52-week high.
Oct 6, 2026 — ROIV dips 0.7% to $35.53
- Closed at $35.53, -0.70% vs the prior close of $35.78. Day range $34.75–$36.34, opened at $35.86.
- Volume was 5.74M shares, 0.7x its 50-day average of 7.69M.
- Price is -3.0% vs its 50-day average ($36.62) and +17.2% vs its 200-day average ($30.31).
- 52-week range $15.25–$42.50; today's close sits at 74% of that range, 16.4% below the 52-week high.
Oct 5, 2026 — ROIV ends flat (+0.2%) to $35.78
- Closed at $35.78, +0.17% vs the prior close of $35.72. Day range $35.24–$36.33, opened at $35.98.
- Volume was 6.20M shares, 0.8x its 50-day average of 7.65M.
- Price is -2.2% vs its 50-day average ($36.60) and +18.3% vs its 200-day average ($30.24).
- 52-week range $15.25–$42.50; today's close sits at 75% of that range, 15.8% below the 52-week high.
Oct 2, 2026 — ROIV rises 0.6% to $35.72
- Closed at $35.72, +0.62% vs the prior close of $35.50. Day range $35.19–$36.00, opened at $35.61.
- Volume was 4.37M shares, 0.6x its 50-day average of 7.65M — lighter than usual.
- Price is -2.4% vs its 50-day average ($36.59) and +18.4% vs its 200-day average ($30.18).
- 52-week range $15.25–$42.50; today's close sits at 75% of that range, 16.0% below the 52-week high.
ROIV latest news & SEC filings
Every SEC filing by or about ROIV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Roivant Sciences Ltd. returned to the company 8,967,383 shares at $5.00 (≈$44.84M) on Oct 1, 2026; now holds 29,880,079
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Epperly Melissa B, converted options/RSUs into 17,750 shares at $4.46 (≈$79.17K) on Oct 1, 2026; now holds 32,704
- Epperly Melissa B, sold 16,850 shares at $36.08 (≈$607.95K) on Oct 1, 2026; now holds 15,854
- Epperly Melissa B, sold 900 shares at $36.57 (≈$32.91K) on Oct 1, 2026; now holds 14,954
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gline Matthew had withheld for taxes 76,171 shares at $36.57 (≈$2.79M) on Sep 30, 2026; now holds 16,583,774
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Torti Frank had withheld for taxes 40,309 shares at $36.57 (≈$1.47M) on Sep 30, 2026; now holds 13,495,893
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sukhatme Mayukh had withheld for taxes 46,879 shares at $36.57 (≈$1.71M) on Sep 30, 2026; now holds 18,583,860
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Venker Eric converted options/RSUs into 200,000 shares at $3.85 (≈$770.00K) on Sep 30, 2026; now holds 1,799,154
- Venker Eric sold 200,000 shares at $36.62 (≈$7.32M) on Sep 30, 2026; now holds 1,599,154
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.44M (prior year $2.17M) (-33.5% vs Jun 30, 2025)
- Net income: -$189.84M (prior year -$223.35M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.26 (prior year -$0.33) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Things to know before you trade ROIV
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 20, 2026, Apr 2, 2026, Feb 6, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.82% (largest 3.7%).
- Liquidity: about 5.75M shares (≈$192.80M) trade per day on average.
- 52-week position: $33.53 vs a range of $16.88–$42.50 (65% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Meghan Fitzgerald sold 400 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 18, 2026; 8-K Sep 8, 2026; 8-K Aug 28, 2026.
- Share count: 722.32M shares outstanding (Jul 31, 2026), +5.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ROIV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 34.12 | 34.12 | 33.23 | 33.53 | 4.92M |
| Oct 15, 2026 | 33.82 | 34.35 | 33.70 | 34.04 | 4.57M |
| Oct 14, 2026 | 33.14 | 34.09 | 33.00 | 33.62 | 4.29M |
| Oct 13, 2026 | 34.44 | 34.92 | 33.26 | 33.35 | 6.32M |
| Oct 12, 2026 | 34.92 | 35.41 | 34.55 | 34.59 | 4.73M |
| Oct 9, 2026 | 34.24 | 35.59 | 34.15 | 35.44 | 5.53M |
| Oct 8, 2026 | 34.28 | 34.56 | 33.32 | 34.21 | 6.40M |
| Oct 7, 2026 | 35.22 | 35.49 | 34.63 | 34.75 | 5.74M |
| Oct 6, 2026 | 35.86 | 36.34 | 34.75 | 35.53 | 5.74M |
| Oct 5, 2026 | 35.98 | 36.33 | 35.24 | 35.78 | 6.20M |
| Oct 2, 2026 | 35.61 | 36.00 | 35.19 | 35.72 | 4.37M |
| Oct 1, 2026 | 36.35 | 36.79 | 35.44 | 35.50 | 3.27M |
| Sep 30, 2026 | 36.77 | 36.96 | 36.23 | 36.57 | 5.28M |
| Sep 29, 2026 | 37.03 | 37.35 | 35.75 | 36.50 | 6.59M |
| Sep 28, 2026 | 35.65 | 37.24 | 35.28 | 36.98 | 6.97M |
| Sep 25, 2026 | 35.98 | 36.19 | 35.51 | 35.80 | 6.76M |
| Sep 24, 2026 | 36.64 | 36.75 | 35.90 | 36.13 | 5.66M |
| Sep 23, 2026 | 38.00 | 38.47 | 36.78 | 36.82 | 9.27M |
| Sep 22, 2026 | 38.73 | 39.17 | 38.11 | 38.22 | 6.75M |
| Sep 21, 2026 | 39.02 | 39.90 | 38.72 | 38.99 | 5.62M |
About Roivant Sciences
Roivant Sciences (ROIV) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LONDON. State of incorporation: Bermuda. Fiscal year ends March 31. SEC CIK 1635088.
ROIV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Melissa B, Epperly | Director | Sep 18, 2026 |
| Meghan Fitzgerald | Director | Sep 18, 2026 |
| Matthew Gline | CEO | Jul 2, 2026 |
| Daniel Allen Gold | Director | Sep 18, 2026 |
| Keith S Manchester | Director | Sep 18, 2026 |
| James C Momtazee | Director | Sep 18, 2026 |
| Ilan Oren | Director | Sep 18, 2026 |
| Mayukh Sukhatme | President & CIO | Aug 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matthew Gline | CEO | Jul 2, 2026 |
| Jennifer Humes | Chief Accounting Officer | Sep 22, 2026 |
| Richard Pulik | CFO | Sep 22, 2026 |
| Mayukh Sukhatme | President & CIO | Aug 21, 2026 |
| Frank Torti | President and Vant Chair | Jul 2, 2026 |
| Eric Venker | President & Immunovant CEO | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 400 | $40.45 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 4,712 | $39.68 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 400 | $40.45 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 4,712 | $39.68 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 400 | $40.45 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 4,712 | $39.68 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 400 | $40.45 |
| Sep 15, 2026 | Meghan Fitzgerald | Sale | 4,712 | $39.68 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 4,338 | $39.65 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 600 | $40.38 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 4,338 | $39.65 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 600 | $40.38 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 4,338 | $39.65 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 600 | $40.38 |
| Sep 15, 2026 | Melissa B, Epperly | Sale | 4,338 | $39.65 |
ROIV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | $8.26M | $-299.77M | -0.54 | $-750.35M |
| Mar 31, 2025 | $29.05M | $-171.98M | -0.24 | $-839.45M |
| Mar 31, 2024 | $32.71M | $4.35B | 5.23 | $-765.27M |
| Mar 31, 2023 | $31.53M | $-1.01B | -1.42 | $-843.39M |
| Mar 31, 2022 | $55.29M | $-845.26M | -1.26 | $-677.73M |
Latest balance sheet: total assets $5.31B, total liabilities $384.62M, cash $1.25B (as of Jun 30, 2026).
ROIV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $35.12 |
| May 20, 2026 | 8-K Item 2.02 (results) | $32.41 |
| Apr 2, 2026 | 8-K Item 2.02 (results) | $28.33 |
| Feb 6, 2026 | 8-K Item 2.02 (results) | $25.82 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $21.17 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $11.17 |
| May 29, 2025 | 8-K Item 2.02 (results) | $11.30 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $10.79 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $11.64 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 30, 2024 | 8-K Item 2.02 (results) | — |
| Feb 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ROIV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.